SUMMARY
Cyclosporin A, a cyclic endecapeptide produced by the fungus species Tolypocladium inflatum Gams, is a potent immunomodulator.l Although the precise mechanism of action is not understood, cyclosporin exerts a selective immunosuppressive effect by blocking an early stage in the activation of cytotoxic T lymphocytes in response to antigen. It may act through a variety of mechanisms including inhibition of the production of interleukin-2 and other cyto kines, inhibition of T cell proliferation and clonal expansion, prevention of the activation of cytotoxic T lymphocytes and inhibition of certain T-cell-depen dent B lymphocyte activity.l- 4 Cyclosporin A has been used systemically, as an immunosuppressant, in the treatment of ocular inflammatory conditions such as Beh<;:et's disease, 5 Vogt Koyanagi Harada syndrome, sympathetic ophthalmitis, birdshot retinochoroidopathy, sarcoido sis and pars planitis.6 Significant nephrotoxicity,1,8 hypertension and hepatotoxicityl have been asso ciated with its use. Topical cyclosporin has been studied in the treatment of corneal graft rejections,9-13 peripheral corneal melting syndrome, outer eye inflammations, vernal conjunctivitis,14 necrotising scleritis,1 5 ligneous conjunctivitis,l6 keratoconjunctivi tis sicca3.17 and ulcerative keratitis,18 and in experi mental herpetic stromal keratitisl9 and experimental autoimmune uveitis.6.20.21 The effect of topical cyclos porin on the immune cells of normal conjunctiva of humans or experimental animals is not known.
Many vehicles for delivery of cyclosporin, such as vegetable oils,9.lo.13 petrolatum-based ointment,22 Cremophorl 1 and alpha-cyclodextrin, 21 have been used but all these resulted in relatively low con centrations of drug to the cornea and anterior Eye (1996) 10,433-438 © 1996 Royal College of Ophthalmologists chamber. 23 The use of collagen shields23 reduced the possibility of adverse systemic effects while achieving higher drug concentration in peripheral target tissues. The use of collagen shields is, however, associated with blurring of vision and consequent poor patient compliance. To overcome the poor compliance of the patient and the blurring effect of collagen corneal shields, we used collagen bits as vehicle for delivery of cyclosporin A.
The Lewis rat model has been used extensively to study immune-mediated diseases, notably experi mental autoimmune uveitis (EAU)2024-26 and corneal graft rejections.12,27,28 It has recently been demonstrated that the conjunctiva is an integral part of the mucosal immune system and that the rat model can be used effectively to study immune responses in conjunctiva-associated lymphoid tissue? The present study was undertaken to assess the effects of topically administered cyclosporin A on the immunocomponent cells of the conjunctiva of Lewis rats and to evaluate the efficacy of a novel method of topical cyclosporin A administration, i.e. collagen bits impregnated with cyclosporin and suspended in artificial tears (Leiras Eye Research, Tampere, Finland).
MATERIALS AND METHODS
Collagen bits (0.5 mm square) impregnated with cyclosporin A drops were suspended in artificial tears (Tears plus: polyvinyl alcohol 1.4%, providone 0.6%) to give a final concentration of 0.5 mg/ml. For controls, plain collagen bits were suspended in Tears plus.
Ten Lewis rats (6-8 weeks old) were divided into three groups. Cyclosporin A/collagen/artificial tears suspension was instilled (10 f.LI) in each eye of 2 rats (group 1) twice daily for 4 days and in 4 rats (group 2) for 8 days. A further 4 rats (group 3) received plain collagen/artificial tears for 8 days and served as controls (Table I) .
At the respective end points (days 4 and 8) all animals in each group were killed and the orbital contents, comprising of eye lids, conjunctiva and eyeball, exenterated en bloc. The tissues were immersed in a cryomatrix of Tissue-Tek OCT com pound (Miles, Kankakee) and snap-frozen in liquid nitrogen. Frozen blocks were wrapped with Parafilm (American National Can) and stored at -20°C until sectioning. Five micrometre, longitudinal sections to include palpebral, forniceal and bulbar conjunctiva of both upper and lower lids were obtained using the Reichert-lung Cryocut 1800 system (Leica, Germany). Sections were placed on precleaned slides, Superfrost plus (Fischer Scientific, Pittsburgh), air-dried over night and stained the next day or wrapped in foil and stored at -20°C before staining. Animals were housed and treated in compliance with the Guidelines for Care and Use of Laboratory Animals (DHEW Publications, NIH 80--23).
Immunohistochemistry
The sensitive alkaline phosphatase/anti-alkaline phosphatase (APAAP) technique was used for immunostaining of tissues. Details of the method are described elsewhere?3 Cryostat sections (10 per specimen) were fixed in acetone for 10 minutes, air dried for 5 minutes and primary antibodies applied in appropriate dilutions (Table II) for 1 hour. Rabbit anti-mouse polyclonal antibody (1:40 for 30 minutes; DAKO, Carpinteria) was used as secondary linking antibody and monoclonal AP AAP mouse (1:40 for 30 minutes; DAKO) was used as the tertiary antibody. Both secondary and tertiary antibodies were absorbed with pooled, heat-inactivated, normal rat serum (20%) for 30 minutes before use. TRIS buffered normal saline (pH 7.6) was used as wash buffer between steps and as negative control. Anti body dilutions were made in the wash buffer. After incubation with tertiary antibody, slides were washed and developed for 15-20 minutes in Fast Red substrate solution. All slides were counterstained with Meyer's haematoxylin and mounted in Gel Mount (Biomeda, Foster City) aqueous mounting medium. Positive, red-stained cells were counted through the entire section including palpebral, forniceal and bulbar conjunctiva of both upper and lower lids (separately for epithelium and substantia propria) at a magnification of x400 by two indepen dent, masked observers and averaged. Cell counts were expressed as numbers per section (including palpebral, forniceal and bulbar conjunctiva of both lids). Variation in counts between the two observers was between 1 % and 3 %. A global significance was first achieved for all the three groups (two experimental groups, day 4 and day 8, and one control group) using the Kruskal Wallis non-parametric analysis of variance (ANOY A). If the global p value was significant, Dunn's multiple comparison procedure (non-para metric) was performed on all pairwise comparisons, at an overall significance level of (ex = ) 0.05. In the second analysis pairwise comparisons between the controls and each treatment group were also performed with the Mann-Whitney U test (non-parametric) with no adjustment for multi ple outcomes. The p values for this were all two tailed.
RESULTS
Externally, all 20 eyes were absolutely normal without any signs of inflammation, congestion or discharge.
On immunohistology of the control group (group 3) (Table III) , we observed a large number of immune cells in the rat conjunctiva. There was a marked preponderance of cells belonging to the macrophage, monocyte, dendritic cell immunophe notype as stained with monoclonal antibodies (Mab) ED1 and ED2. In general, the greater proportion of all cell types were located in the substantia propria as compared with the epithelium -except for cells staining positive for the interleukin-2 (IL2) receptor (CD25), which were present in a greater proportion in the epithelium. CD8 positive (OX-8) cells were almost equally distributed between the two locations.
Analysis of the comparison of individual cell types in conjunctiva of the control group with that of conjunctiva of the two groups treated with cyclo sporin A (Table III) revealed, in general, a decrease in the population of all cell types. In the control group over 80% of T lymphocytes, bearing the pan T cell marker (W3/13, CD3), were situated in the substantia propria. In cyclosporin A treated groups the conjunctiva showed a decrease in T lymphocytes, which was most marked in group 2 (8 days of cyclosporin A), to 20% of the control group intraepithelially and 12 % of the control in the substantia propria. Similarly in controls, about 90% of the cells staining with Mab W3/25 (CD4, T helpers and macrophages) were found in the substantia propria, with the intraepithelial population account ing for approximately 9%. The cyclosporin A treated groups again showed a reduced population of these cells to under 22 % of controls intraepithelially and 55 % of controls in the substantia propria. The suppressor/cytotoxic T lymphocytes (OX-8, CD8) were more evenly distributed between intra epithelial and substantia propria locations. They were reduced to just over 30% of the control group intraepithelially and to 50% in the substantia propria, by day 8 of cyclosporin A administration.
Cells staining positive for interleukin-2 (IL2) receptor (MRC OX-39, CD25) were observed more in the intraepithelial location than in the substantia propria. A significant effect of cyclosporin A was noticed in the cell population of group 2, with a reduction of positive cells to 6% intraepithelially and to 21 % in the substantia propria. Interestingly, the contents of the goblet cells also stained positive with Mab OX-39 (IL2 receptor, CD25) in all conjunctival sections of controls (Fig. 1) . Cyclosporin A treatment for 8 days completely abolished OX-39 (CD25) staining of goblet cells (Fig. 2) . In the controls, cells expressing the MHC class II, Ia antigen (MRC OX-6) were 3 times more numerous in the substantia propria than in the epithelium. After 8 days of cyclosporin A treatment (group 2), OX-6 positive cells had decreased to under 60% of controls in the epithelium and to just over 40% in the substantia propria.
Cells staining positively with Mab EDI (macro phages, monocytes and dendritic cells) and ED2 (macrophages) were by far the largest population of the cells observed, and were found almost entirely (92-97%) in the substantia propria. Compared with the controls, in cyclosporin A treated animals (group 2) EDI positive cells had decreased to 40% and ED2 positive cells to 14% in the epithelium and to 65% (EDl) and 67% (ED2) in the substantia propria.
B cells, as stained with the anti-IgD heavy chain antibody MARD-3, were the least prevalent of all cell types, with the majority (76%) in the substantia propria. The B cell population was not significantly reduced by cyclosporin A treatment. however, remains blurred until dissolution of the collagen shield is complete. Results of our study indicate that collagen bits offer an effective alter native method for the topical administration of cyclosporin A. Although we have not used this preparation in humans, its effect on vision and symptoms of irritation is expected to be relatively less. The animals eyes did not show any signs of irritation, in the form of redness, watering or lid swelling, during the course of treatment. The efficacy of this method of drug delivery was supported by the observed immunosuppressant effect of cyclosporin A on the immunocompetent cells of the conjunctiva.
In this study, the rat conjunctiva of the control group presented a similar immunophenotypical dis tribution of lymphocytes and other immunocompe tent cells to that seen in the human conjunctiva?3 The results of the control group are similar to our recent study reporting the normal profile of immu nocompetent cells in rat CALT (submitted).
Cyclosporin A is believed to exert its immunosup pressive effect through a variety of mechanisms, including inhibition of the production of IL2 and other cytokines, inhibition of T cell proliferation and clonal expansion, prevention of the activation of cytotoxic T lymphocytes and inhibition of certain T cell-dependent B lymphocyte activity.1-3 Inhibition of T lymphocyte activation is critical to the immu nosuppressive effect. Cyclosporin A interferes with T lymphocyte ability to produce the lymphokine IL2 or respond to IL2' by preventing the formation of specific IL2 receptors. This lymphokine is thought to be the primary path by which T lymphocytes continue to recruit and activate new T cells. The expression of IL2 receptor (CD25) is critical for the T cell capacity to respond to this lymphokine. 4 Immunohistochemistry of the conjunctiva of eyes treated with cyclosporin A for 4 and 8 days showed a gradual decrease in the populations of all immuno component cells. There was significant decrease in the total number of T lymphocytes, with the greatest decrease in the cells expressing IL2 receptors (OX-39, CD25 intraepithelial) and cytotoxic/suppre&'ior T lymphocytes (OX-8, CD8). A decrease in W3/25 (CD4) bearing cells suggests a decrease in T helpers, but it has to be kept in mind that this antibody also stains macrophages. A morphological distinction between lymphocytes and macrophages was not attempted.
A decrease in the number of macrophages, monocytes and cells expressing MHC classs II, Ia antigen was observed. Similar results were found in human conjunctiva in ligneous conjunctivitis after treatment with topical cyclosporin prepared in olive oil. 16 It is interesting to note that although cyclo sporin specifically targets the T helper/inducer subset of lymphocytes its 'knock-on' effect results in a generalised suppression of all cell types including mononuclear cells, with the exception perhaps of B lymphocytes.
Our study supports the notion that local immuno suppression can be achieved by the topical adminis tration of cyclosporin A in rats, and also indicates that cyclosporin A can affect the population of immunocompetent cells in normal conjunctiva. The Lewis rat should prove to be a good model for immunological studies of the ocular surface.
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